Alpha 2.0
Login Register
» Articles » PMID: 18444798

CD8(+) T Cell Activation in Women Coinfected with Human Immunodeficiency Virus Type 1 and Hepatitis C Virus

Overview
Journal J Infect Dis
Publisher Oxford University Press
Specialty Infectious Diseases
Date 2008 May 1
PMID 18444798
Citations 53
Authors
Andrea Kovacs
Lena Al-Harthi
Shawna Christensen
Wendy Mack
Mardge Cohen
Alan Landay
Affiliations
Soon will be listed here.
Abstract

Immune activation is a hallmark of human immunodeficiency virus type 1 (HIV-1) infection and impacts innate and adaptive immunity. Individuals coinfected with HIV-1 and hepatitis C virus (HCV) may have increased immune activation early in HIV disease because of a high HCV antigen load in tissues such as the liver. We evaluated T cell markers of activation and maturation in women with or without HIV-1 infection, by HCV antibody and HCV RNA status. We found increased percentages of activated CD8(+) T cells (i.e., CD8(+)HLA-DR(+)38(+) cells and CD8(+)CD28(+)HLA-DR(+) cells) but not of CD4(+) T cells among women who tested positive for HIV-1, HCV antibody, and HCV RNA, compared with HIV-1-positive women who tested negative for HCV antibody. Because CD8(+) T cell activation is related to HIV-1 disease progression, these data may have implications for the medical management of patients coinfected with HIV-1 and HCV.

Citing Articles

Limited restoration of T cell subset distribution and immune function in older people living with HIV-1 receiving HAART.

Li N, Zheng H, Li W, He X, Zhang M, Li X Immun Ageing. 2025; 22(1):3.

PMID: 39780181 PMC: 11708165. DOI: 10.1186/s12979-024-00497-2.

The Era of DAAs: Assessing the Patients' Characteristics, Clinical Impact, and Emergence of Comorbidities in HIV/HCV-Coinfected versus HIV-Infected Individuals.

Alvarez-Alvarez B, Prieto-Perez L, De la Cuadra-Grande A, Casado M, Cabello Ubeda A, Al-Hayani A J Clin Med. 2024; 13(13).

PMID: 38999501 PMC: 11242478. DOI: 10.3390/jcm13133936.

Proprotein convertase subtisilin/kexin 9 levels decline with hepatitis C virus therapy in people with HIV/hepatitis C virus and correlate with inflammation.

Gandhi M, Nguyen K, Lake J, Liao D, Khodabakhshian A, Guerrero M AIDS. 2023; 38(3):317-327.

PMID: 37788081 PMC: 10841736. DOI: 10.1097/QAD.0000000000003739.

So Pathogenic or So What?-A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research.

Kleinman A, Pandrea I, Apetrei C Viruses. 2022; 14(1).

PMID: 35062339 PMC: 8781889. DOI: 10.3390/v14010135.

Hepatitis C coinfection and extrahepatic cancer incidence among people living with HIV.

Willis S, Kim H, Achenbach C, Cachay E, Christopoulos K, Crane H HIV Med. 2021; 23(6):620-628.

PMID: 34951105 PMC: 9177743. DOI: 10.1111/hiv.13218.

References
1.
van Lier R, Ten Berge I, Gamadia L . Human CD8(+) T-cell differentiation in response to viruses. Nat Rev Immunol. 2003; 3(12):931-9. DOI: 10.1038/nri1254. View
2.
Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H . Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 2000; 356(9244):1800-5. DOI: 10.1016/s0140-6736(00)03232-3. View
3.
Sulkowski M, Moore R, Mehta S, Chaisson R, Thomas D . Hepatitis C and progression of HIV disease. JAMA. 2002; 288(2):199-206. DOI: 10.1001/jama.288.2.199. View
4.
Lucas M, Vargas-Cuero A, Lauer G, Barnes E, Willberg C, Semmo N . Pervasive influence of hepatitis C virus on the phenotype of antiviral CD8+ T cells. J Immunol. 2004; 172(3):1744-53. DOI: 10.4049/jimmunol.172.3.1744. View
5.
Weis N, Lindhardt B, Kronborg G, Hansen A, Laursen A, Christensen P . Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study. Clin Infect Dis. 2006; 42(10):1481-7. DOI: 10.1086/503569. View